To further nuance the relation between ω-3 and AD risk, the recent results of a large US-based cohort study (N = 1,670) suggested that, despite substantial AD risk in the general ApoE ε4+ population, there was no evidence of difference in AD risk between ApoE ε4+ and ApoE ε4− individuals when ω-3 supplementation was both high and long-term [(143), Figures 4a, b]. Here, APOE is linked to Alzheimer disease.